Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report
Abstract Background Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disease characterized by the presence of renal cysts. Over time the expanding cysts lead to progressive renal failure. The use of tolvaptan, a V2-receptor antagonist, was recently approved in ADPKD patients. It...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-11-01
|
| Series: | BMC Nephrology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12882-019-1612-7 |
| _version_ | 1818531727559098368 |
|---|---|
| author | Angela Maria Pellegrino Luigi Annicchiarico Petruzzelli Eleonora Riccio Antonio Pisani |
| author_facet | Angela Maria Pellegrino Luigi Annicchiarico Petruzzelli Eleonora Riccio Antonio Pisani |
| author_sort | Angela Maria Pellegrino |
| collection | DOAJ |
| description | Abstract Background Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disease characterized by the presence of renal cysts. Over time the expanding cysts lead to progressive renal failure. The use of tolvaptan, a V2-receptor antagonist, was recently approved in ADPKD patients. It was demonstrated that tolvaptan get slower decline in Kidney function compared with placebo. Idiosyncratic hepatic toxicity was described in patients receiving tolvaptan, with elevations in aminotransferases levels. We describe the first case reported in the literature in which hepatic toxicity is caused by the association of amoxicillin/clavulanic acid and tolvaptan. Case presentation A 41 years old woman with diagnosis of ADPKD had been in treatment with tolvaptan for 16 weeks when an elevation of liver enzyme levels was detected. She had taken autonomously amoxicillin/clavulanic acid (in doses of 825/175 mg twice a day for 7 days) about 5 weeks before. The timing of the event and the kind of hepatocellular injury could be attributed to the concomitance of medication of tolvaptan and amoxicillin/clavulanic acid. Conclusion We highlight the need to careful monitor hepatic enzyme levels in order to recognize early hepatic side effects in ADPKD patients in treatment with tolvaptan and amoxicillin/clavulanic acid. |
| first_indexed | 2024-12-11T17:36:14Z |
| format | Article |
| id | doaj.art-0113569229e8433aba91f858212613b4 |
| institution | Directory Open Access Journal |
| issn | 1471-2369 |
| language | English |
| last_indexed | 2024-12-11T17:36:14Z |
| publishDate | 2019-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Nephrology |
| spelling | doaj.art-0113569229e8433aba91f858212613b42022-12-22T00:56:39ZengBMCBMC Nephrology1471-23692019-11-012011410.1186/s12882-019-1612-7Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case reportAngela Maria Pellegrino0Luigi Annicchiarico Petruzzelli1Eleonora Riccio2Antonio Pisani3Department of Public Health, Nephrology Unit, University of Naples “Federico II”Department of Public Health, Nephrology Unit, University of Naples “Federico II”Department of Public Health, Nephrology Unit, University of Naples “Federico II”Department of Public Health, Nephrology Unit, University of Naples “Federico II”Abstract Background Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disease characterized by the presence of renal cysts. Over time the expanding cysts lead to progressive renal failure. The use of tolvaptan, a V2-receptor antagonist, was recently approved in ADPKD patients. It was demonstrated that tolvaptan get slower decline in Kidney function compared with placebo. Idiosyncratic hepatic toxicity was described in patients receiving tolvaptan, with elevations in aminotransferases levels. We describe the first case reported in the literature in which hepatic toxicity is caused by the association of amoxicillin/clavulanic acid and tolvaptan. Case presentation A 41 years old woman with diagnosis of ADPKD had been in treatment with tolvaptan for 16 weeks when an elevation of liver enzyme levels was detected. She had taken autonomously amoxicillin/clavulanic acid (in doses of 825/175 mg twice a day for 7 days) about 5 weeks before. The timing of the event and the kind of hepatocellular injury could be attributed to the concomitance of medication of tolvaptan and amoxicillin/clavulanic acid. Conclusion We highlight the need to careful monitor hepatic enzyme levels in order to recognize early hepatic side effects in ADPKD patients in treatment with tolvaptan and amoxicillin/clavulanic acid.http://link.springer.com/article/10.1186/s12882-019-1612-7ADPKDTolvaptanAmoxicillin/clavulanic acidHepatic toxicity |
| spellingShingle | Angela Maria Pellegrino Luigi Annicchiarico Petruzzelli Eleonora Riccio Antonio Pisani Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report BMC Nephrology ADPKD Tolvaptan Amoxicillin/clavulanic acid Hepatic toxicity |
| title | Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report |
| title_full | Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report |
| title_fullStr | Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report |
| title_full_unstemmed | Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report |
| title_short | Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report |
| title_sort | idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease adpkd patient in combined treatment with tolvaptan and amoxicillin clavulanic acid a case report |
| topic | ADPKD Tolvaptan Amoxicillin/clavulanic acid Hepatic toxicity |
| url | http://link.springer.com/article/10.1186/s12882-019-1612-7 |
| work_keys_str_mv | AT angelamariapellegrino idiosyncratichepatictoxicityinautosomaldominantpolycystickidneydiseaseadpkdpatientincombinedtreatmentwithtolvaptanandamoxicillinclavulanicacidacasereport AT luigiannicchiaricopetruzzelli idiosyncratichepatictoxicityinautosomaldominantpolycystickidneydiseaseadpkdpatientincombinedtreatmentwithtolvaptanandamoxicillinclavulanicacidacasereport AT eleonorariccio idiosyncratichepatictoxicityinautosomaldominantpolycystickidneydiseaseadpkdpatientincombinedtreatmentwithtolvaptanandamoxicillinclavulanicacidacasereport AT antoniopisani idiosyncratichepatictoxicityinautosomaldominantpolycystickidneydiseaseadpkdpatientincombinedtreatmentwithtolvaptanandamoxicillinclavulanicacidacasereport |